Table 5.
Correlation between VLDLR II expression and clinical features in 51 Lung cancer patients
| Parameters | Number | VLDLR II fold | P |
|---|---|---|---|
| Age at diagnosis | |||
| ≥ 55 years | 30 | 1.16 ± 0.25 | 0.781 |
| < 55 years | 21 | 1.11 ± 0.34 | |
| Gender | |||
| Male | 35 | 1.12 ± 0.31 | 0.424 |
| Female | 16 | 1.19 ± 0.37 | |
| Body weight | |||
| ≥ 60 kg | 19 | 1.15 ± 0.22 | 0.823 |
| < 60 kg | 32 | 1.13 ± 0.32 | |
| TC | |||
| > 5.20 mmol/L | 12 | 1.03 ± 0.20 | 0.096 |
| ≤ 5.20 mmol/L | 39 | 1.16 ± 0.30 | |
| TG | |||
| > 1.70 mmol/L | 9 | 1.01 ± 0.35 | 0.166 |
| ≤ 1.70 mmol/L | 42 | 1.17 ± 0.27 | |
| Histological grade | |||
| Well to moderately differentiated | 38 | 1.11 ± 0.29 | 0.133 |
| Poorly differentiated | 13 | 1.25 ± 0.27 | |
| Tumor size | |||
| ≥ 5 cm | 22 | 1.20 ± 0.30 | 0.254 |
| < 5 cm | 29 | 1.09 ± 0.28 | |
| Lymph node metastasis | |||
| Negative | 15 | 1.01 ± 0.37 | 0.090 |
| Positive | 36 | 1.19 ± 0.23 | |
| Distant metastasis | |||
| Negative | 40 | 1.06 ± 0.26 | 0.008* |
| Positive | 11 | 1.36 ± 0.29 | |
| TNM stage | |||
| Stage I-II | 25 | 1.06 ± 0.27 | 0.061 |
| Stage III-IV | 26 | 1.25 ± 0.29 | |
| Histological type | |||
| adenocarcinoma | 18 | 1.22 ± 0.29 | 0.190 |
| squamous cell carcinoma | 24 | 1.11 ± 0.31 | |
| small cell carcinoma | 6 | 1.03 ± 0.19 | |
| adeno-squamous carcinoma | 3 | 1.09 ± 0.07 |
Folds (VLDLR II protein in tumor/in normal) in mean ± SD. VLDLR II measured by Western blot. TC, total cholesterol (normal range: ≤ 5.20 mmol/L); TG, triglycerides (normal range: ≤ 1.70 mmol/L). Statistical analyses were performed by Mann-Whitney test (for 2 groups) or Kruskal-Wallis test (for > 2 groups).
*P < 0.05 is considered significant.